Exenatide extended release (Bydureon)

For adult patients uncontrolled on one or more antidiabetic oral agents in addition to diet and exercise.

In a 24 week clinical trial versus Exenatide it decreased Hemoglobin A1C hemoglobin by 1.6%.

Slows gastric emptying time and can reduce the rate of absorption of orally administered drugs.

Can increase INR in patients on warfarin therapy.

Leave a Reply

Your email address will not be published. Required fields are marked *